Complete cross strain protection against congenital cytomegalovirus infection requires a vaccine encoding key antibody (gB) and T-cell (immediate early 1 protein) viral antigens
Complete cross-strain cCMV protection is a significant milestone in this model and is achieved by the inclusion of an antibody response to trimeric gB and T-cell response to IE1. Importantly, gB and IE1 responses can synergize and increase protection against cCMV, unlike prior approaches with gB and pp65 tegument proteins.
Authors
- Nadia S. El‐Hamdi (ORCID: https://orcid.org/0000-0001-9664-0763)
- Yushu Qin (ORCID: https://orcid.org/0000-0002-5198-4818)
- Alistair McGregor (ORCID: https://orcid.org/0000-0002-5994-516X)
- K. Yeon Choi (ORCID: https://orcid.org/0000-0003-0859-4045)
Institutions
- Texas A&M Health Science Center (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.3389/fimmu.2025.1649656
- Citations
- 1
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Robert Koch Institut
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases